- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Tezepelumab
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 4:16 AM EDT